Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
Authors:
Top Cited Papers
Open Access
- 10 March 2025
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 43 (3) , 503-518.e10
Abstract
No abstract availableKeywords
Funding Information
- Central Committee of China Communist Party
- National Program for Support of Top-notch Young Professionals
- National Natural Science Foundation of China (82121002, 82173301)
This publication has 84 references indexed in Scilit:
- The hallmarks of cancer immune evasionCancer Cell, 2024
- Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitmentCancer Cell, 2023
- STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activationNano Research, 2022
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeCell, 2019
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaCell, 2018
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell, 2018
- TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFNEuropean Journal of Immunology, 2014
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune ResponsesCancer Cell, 2014